Allogeneic bone marrow transplant (BMT) is an essential treatment to cure patients with blood cancers such as leukemia.
Dr. Goodman is also involved in collaborative efforts with the San Antonio Bone Marrow Transplant Center to study the outcome of
allogeneic bone marrow transplants following a relapse from autologous bone marrow transplants.
Not exact matches
The only documented long - term complete remissions reported in multiple myeloma patients have occurred with
allogeneic bone marrow transplantation, where a donor's blood stem cells (graft) are
transplanted into the patient (host) with multiple myeloma.
Board - certified in internal medicine and medical oncology, Dr. Collins has 25 years of experience in
bone marrow transplantation and has participated in some 2,500 autologous and
allogeneic transplants.
In the future, outpatient blood and
bone marrow stem cell transplantation will be offered to a broader group of patients with other blood disorders and for
allogeneic transplants (
transplant from non-twin donor stem cells).
Patients receive one of two types of stem cell - based
transplants: autologous, in which a patient donates and receives back his / her own stem cells; or
allogeneic, in which
bone marrow - derived stem cells come from a related or unrelated donor whose human leukocyte antigens (HLA) are genetically matched with those of a patient.
Our expertise includes both autologous and
allogeneic stem cell
transplants (using cells directly from the patient and from another person, respectively), using cells derived from
bone marrow, peripheral blood and cord blood.
Ponatinib Extends Survival Over
Transplant in Chronic Phase CML: The results of a new study that included patients from the PACE trial and the European
Bone Marrow Transplant registry revealed that treatment with ponatinib yielded better overall survival (OS) compared with
allogeneic stem cell transplantation (allo - SCT) in patients with chronic phase chronic myeloid leukemia (CP - CML) with a T315I mutation.